Why Endo International (ENDP) Stock Is Up in After-Hours Trading Today

NEW YORK (TheStreet) -- Shares of Endo International  (ENDP) rose 2.81% to $67 in after-hours trading Tuesday after the company announced a proposal to acquire Auxilium Pharmaceuticals  (AUXL) in a cash-and-stock deal valued at $2.2 billion.

Endo offered $28.10 a share, which represents a 31% premium to Auxilium's Tuesday closing price of $21.52.

Endo acquired Canadian drug maker Paladin Labs in November 2013. Auxilium, meanwhile, had agreed in June to merge with Canadian biopharmaceutical company QLT in a tax-cutting measure. Should Auxilium accept Endo's offer, the QLT merger would be canceled.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Auxilium announced earlier this month it would cut 30% of its staff in an effort to sharpen its research and development focus and reduce its annual costs by $75 million. The smaller Auxilium would have two sales groups instead of three. The company had 639 employees at the end of 2013 and planned to reduce that figure by approximately 200.

ENDP Chart ENDP data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists